First American Bank Acquires 1,299 Shares of Boston Scientific Co. (NYSE:BSX)

First American Bank increased its stake in shares of Boston Scientific Co. (NYSE:BSX) by 1.0% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 130,133 shares of the medical equipment provider’s stock after buying an additional 1,299 shares during the quarter. First American Bank’s holdings in Boston Scientific were worth $11,623,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of BSX. MONECO Advisors LLC grew its holdings in shares of Boston Scientific by 7.6% in the third quarter. MONECO Advisors LLC now owns 3,861 shares of the medical equipment provider’s stock valued at $324,000 after purchasing an additional 272 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its holdings in Boston Scientific by 9.7% in the third quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,352 shares of the medical equipment provider’s stock valued at $115,000 after purchasing an additional 119 shares during the period. Oak Harvest Investment Services lifted its stake in Boston Scientific by 60.7% in the third quarter. Oak Harvest Investment Services now owns 11,250 shares of the medical equipment provider’s stock worth $943,000 after acquiring an additional 4,250 shares during the last quarter. S.A. Mason LLC raised its stake in Boston Scientific by 6.1% in the third quarter. S.A. Mason LLC now owns 2,335 shares of the medical equipment provider’s stock valued at $196,000 after buying an additional 135 shares in the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. acquired a new stake in shares of Boston Scientific during the 3rd quarter worth about $30,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Activity

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $90.78, for a total transaction of $633,916.74. Following the completion of the sale, the executive vice president now directly owns 29,308 shares in the company, valued at approximately $2,660,580.24. This trade represents a 19.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the completion of the sale, the executive vice president now owns 5,502 shares of the company’s stock, valued at $560,103.60. The trade was a 75.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 144,305 shares of company stock worth $14,954,985. 0.50% of the stock is currently owned by insiders.

Boston Scientific Trading Down 0.9 %

Shares of BSX stock opened at $100.66 on Friday. The company has a market cap of $148.56 billion, a P/E ratio of 80.53, a PEG ratio of 2.79 and a beta of 0.80. Boston Scientific Co. has a fifty-two week low of $65.52 and a fifty-two week high of $107.17. The stock has a 50 day simple moving average of $98.97 and a two-hundred day simple moving average of $90.03. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Research analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Royal Bank of Canada raised their price objective on Boston Scientific from $105.00 to $116.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Boston Scientific in a report on Thursday, February 6th. Deutsche Bank Aktiengesellschaft upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a research note on Friday, January 10th. StockNews.com lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Finally, Barclays raised their price target on Boston Scientific from $111.00 to $118.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Two equities research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $107.39.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.